Nausea and Vomiting Clinical Trial
Official title:
Observation on the Efficacy of Three Antiemetics in Preventing Nausea and Vomiting Caused by Intravenous Tramadol Injection and Postoperative Nausea and Vomiting
Verified date | December 2022 |
Source | The Second Affiliated Hospital of Chongqing Medical University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To explore the effect of commonly used antiemetic drugs on reducing nausea and vomiting caused by intravenous tramadol injection, so as to reduce the incidence of nausea and vomiting in clinical use of tramadol and provide guidance for the clinical use of tramadol injection
Status | Completed |
Enrollment | 200 |
Est. completion date | November 3, 2023 |
Est. primary completion date | October 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - American Society of Anesthesiologists classification I-II - 18.5=BMI=28 - Patients who receiving breast and thyroid surgery and requiring general anesthesia and receive PCIA - Voluntarily and be able to understand and sign the informed consent form Exclusion Criteria: - Long-term use of analgesics, psychotropic drugs (including opioids, NSAIDS, antidepressants) history - History of allergy to opioids - Patients with a history or family history of epilepsy that has not been controlled by treatment - Sedatives and antidepressants were used 24 hours before surgery - Failure to cooperate with the study for any reason or in the opinion of the investigator |
Country | Name | City | State |
---|---|---|---|
China | The Second Affiliated Hospital, Chongqing Medical University | Chongqing | Chongqing |
Lead Sponsor | Collaborator |
---|---|
The Second Affiliated Hospital of Chongqing Medical University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | NRS score of nausea and vomiting | NRS score of nausea and vomiting was assessed by numerical rating scale (0-10, 0 representing no nausea and 10 the worst nausea imaginable) | From before administration to 10min after administration | |
Secondary | Incidence of postoperative nausea and vomiting | PONV is recorded according to whether the patient present nausea and vomiting during the follow-up visits after surgery | From end of operation to 24 hours after operation | |
Secondary | NRS score of postoperative nausea and vomiting | NRS score of nausea and vomiting was assessed by numerical rating scale (0-10, 0 representing no nausea and 10 the worst nausea imaginable) | From end of operation to 24 hours after operation | |
Secondary | Incidence of extra treatment for postoperative nausea and vomiting | Incidence of extra treatment for postoperative nausea and vomiting was assessed by whether patient using other treatment for postoperative nausea and vomiting during the the follow-up visits after surgery | From end of operation to 24 hours after operation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05016180 -
Effect of Ultrasound-guided Transversus Abdominis Plane Block After Laparoscopic Bariatric Surgery
|
Phase 2 | |
Withdrawn |
NCT00891761 -
A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy
|
Phase 3 | |
Terminated |
NCT00903396 -
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
|
Phase 2 | |
Recruiting |
NCT01696734 -
Domperidone in Treating Patients With Gastrointestinal Disorders
|
Phase 3 | |
Completed |
NCT00293384 -
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
|
N/A | |
Completed |
NCT00006348 -
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
|
Phase 3 | |
Completed |
NCT00004895 -
Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery
|
Phase 2 | |
Completed |
NCT00003817 -
Acupressure and Acustimulation Wrist Bands for the Prevention of Nausea and Vomiting Caused by Chemotherapy
|
Phase 2 | |
Active, not recruiting |
NCT06045364 -
Effect of Glycopyrrolate on Nausea and Vomiting After ERCP Operation
|
Phase 1/Phase 2 | |
Completed |
NCT00978185 -
Acupressure Wristbands or Standard Care in Controlling Nausea Caused by Chemotherapy
|
Phase 3 | |
Completed |
NCT00064272 -
UMCCOP 02-01 Ginger in Treating Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer
|
Phase 2 | |
Completed |
NCT00003213 -
Drugs to Reduce the Side Effects of Chemotherapy
|
Phase 3 | |
Recruiting |
NCT05690802 -
The Safety and Effectiveness of Palonosetron Hydrochloride Capsule Was Used to CINV
|
N/A | |
Recruiting |
NCT06314906 -
Electroacupuncture Plus Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer
|
Phase 3 | |
Completed |
NCT00590317 -
Ondansetron vs Prochlorperazine for Nausea and Vomiting in the Emergency Department
|
Phase 2 | |
Completed |
NCT03185156 -
The Preventive Effects of Sub Hypnotic Dose of Propofol for Nausea and Vomiting Induced by Hemabate
|
Phase 4 | |
Not yet recruiting |
NCT06382012 -
Antiemetic Fosaprepitant To Remedy Nausea and Vomiting
|
Phase 2/Phase 3 | |
Completed |
NCT01590147 -
Supportive Intervention Programs Study
|
N/A | |
Terminated |
NCT01275664 -
Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer
|
N/A | |
Completed |
NCT00381862 -
Phase II Trial Evaluating the Efficacy and Tolerability of Aprepitant & Palonosetron for Prevention of Chemotherapy-Induced Nausea and Vomiting
|
Phase 2 |